Related Experiment Video

Updated: Jul 4, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Metastatic renal cell carcinoma: recent advances and current therapeutic options

Andres Jan Schrader1, Rainer Hofmann

  • 1Department of Urology, Philipps University Medical School, Baldingerstrasse, 35043 Marburg, Germany. ajschrader@gmx.de

Anti-Cancer Drugs
|May 31, 2008
PubMed

Insights

New targeted therapies show promise for metastatic renal cell carcinoma, offering improved options beyond traditional immuno(chemo)therapy. Research in 2007 highlights tyrosine kinase inhibitors and monoclonal antibodies as key advancements.

Area of Science:

  • Oncology
  • Translational Medicine
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment historically relied on immuno(chemo)therapy with limited efficacy and significant toxicity.
  • Recent breakthroughs in understanding mRCC biology and genetics have paved the way for novel therapeutic strategies.

Purpose of the Study:

  • To provide a concise overview of current clinical trial results in mRCC published in 2007.
  • To translate these findings into actionable therapeutic options and clinical recommendations for mRCC management.

Main Methods:

  • Review of clinical trials in metastatic renal cell carcinoma published within the 2007 timeframe.
  • Analysis of emerging drug classes including small molecule tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and monoclonal antibodies.

Main Results:

  • Several novel targeted agents have demonstrated promising activity in clinical trials for mRCC.
  • Small molecule tyrosine kinase inhibitors, mTOR inhibitors, and monoclonal antibodies represent the most promising therapeutic classes.

Conclusions:

  • Targeted therapies represent a significant advancement in the treatment of metastatic renal cell carcinoma.
  • The results from 2007 trials offer new therapeutic avenues and inform clinical decision-making for mRCC patients.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...